Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Novo Nordisk said a new weight-loss drug candidate led to weight loss and diabetes reductions in both injection and pill versions during a mid-stage trial.

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

Women who have rebound weight gain after stopping Wegovy or similar jabs end up gaining more weight during pregnancy, leading ...

Four in five people put the weight back on after coming off weight loss jabs, new research has suggested today—and they're ...

Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling ...

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...